Latest News
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
7 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that US regulators have granted accelerated approval for Etcamah (camizestrant), its next-generation oral selective oestrogen receptor degrade...
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pelacarsen did not meet its primary endpoint of reduci...
Aptar and Aceso Therapeutics partner to advance inhaled cystic fibrosis therapy
7 September 2026 - Aptar Pharma, a provider of drug delivery, dosing, protection technologies and services and part of AptarGroup Inc (NYSE:ATR), announced on Monday that it has partnered with Aceso Therapeutics, a biotech developing novel therapies ...
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
7 September 2026 - Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Friday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant) in p...
4basebio announces expansion of DNA offering for personalised mRNA medicines
7 September 2026 - Synthetic DNA 4basebio PLC (AIM: 4BB) declared on Monday that it has expanded its DNA offering to support production of critical starting material for personalised mRNA medicines.The expanded offering across the company's high...